RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaApril 26, 2024 – Washington- A House committee next month plans to mark up legislation that would restrict U.S. biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. The goal is for the House to pass the bill
before the July 4 recess, setting it up to be included in a year-end must-pass legislative package.
The BIOSECURE Act was written by leaders of the Select Committee on the Chinese Communist Party, in response to fears that Chinese biotechnology companies could threaten U.S. national security if they give the Chinese government access to sensitive health information about Americans.
https://www.statnews.com/2024/04/26/momentum-builds-for-house-bill-cracking-down-on-chinese-biotechs/ March 29, 2024 - China-based biotech
WuXi AppTec allegedly
handed a U.S. client’s intellectual property over to the Chinese government without consent, according to an exclusive Reuters report on Thursday.
Citing sources who requested anonymity, Reuters reported that U.S. intelligence officials—led by the Federal Bureau of Investigation, the State Department and the Office of the Director of National Intelligence—told senators about WuXi’s IP transfer in a classified briefing.
The intelligence officials informed the lawmakers that WuXi and other China-affiliated entities had “engaged in activity in the U.S. contrary to U.S. national security interests,” Reuters reported.
https://www.biospace.com/article/wuxi-apptec-shared-client-ip-with-beijing-say-us-intelligence-officials-reuters/